tbuckley/cabot-search huggingface dataset:
Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors
Authors: Bart C. Kuenen, Lee Rosen, Egbert F. Smit, Mandy R.N. Parson, Marcel Levi, Rita Ruijter, Holger Huisman, Marc A. Kedde, Paul Noordhuis, Wim J.F. van der Vijgh, Godefridus J. Peters, Gillian F. Cropp, Paul Scigalla, Klaus Hoekman, Herbert M. Pinedo, Giuseppe Giaccone
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To investigate the feasibility and pharmacokinetics of the combination cisplatin, gemcitabine, and SU5416. PATIENTS AND METHODS: Patients received cisplatin 80 mg/m 2 on day 1, gemcitabine 1,250 mg/m 2 on days 1 and 8, repeated every 3 weeks, and SU5416 (85 and 145 mg/m 2 ) intravenously twice weekly. Pharmacokinetics of all three agents, side effects, and antitumor response were investigated in patients with solid tumors amenable to therapy with cisplatin/gemcitabine. RESULTS: In the first cohort of three patients entered at the 85 mg/m 2 dose, no dose-limiting toxicities were observed. In the next cohort (145 mg/m 2 ), three patients developed a thromboembolic event. After entry was restricted to patients with low thromboembolic risk, three additional patients enrolled at 145 mg/m 2 developed a thromboembolic event. The dose was then reduced to 85 mg/m 2 in all patients still on the study, and three additional patients were entered on this dose level. In 19 treated patients, eight patients developed nine thromboembolic events (three transient ischemic attacks, two cerebrovascular accidents, and four deep venous thromboses). The most common toxicities observed were those previously reported for SU5416 alone (headache and phlebitis) and for this chemotherapy regimen (nausea, thrombocytopenia, and leucopenia). No significant pharmacologic interaction among the three drugs was observed. Response rates were similar to those expected in the patient population selected for this study. Analysis of variables of the coagulation cascade and of vessel wall activation was performed in three patients and showed significant increases in thrombin generation and endothelial cell perturbation in a treatment cycle–dependent manner. CONCLUSION: The incidence of thromboembolic events, possibly related to the particular regimen tested in this study, discourages further investigation of this regimen.
Necrological Report.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health Disparities Experienced by Hispanics—United States
Journal: JAMA (2004)

In the 2000 census, 35.3 million persons in the United States and 3.8 million persons in the Commonwealth of Puerto Rico identified themselves as Hispanic (i.e., Hispanic, Spanish, or Latino; of all races). Hispanics constituted 12.5% of the U.S. population in the 50 states; by subpopulation, they identified as Mexican (7.3%), Puerto Rican (1.2%), Cuban (0.4%), and other Hispanic (3.6%). For certain health conditions, Hispanics bear a disproportionate burden of disease, injury, death, and disability when compared with non-Hispanic whites, the largest racial/ethnic population in the United States. The leading causes of death among Hispanics vary from those for non-Hispanic whites. This week's MMWR is the second in a series focusing on racial/ethnic health disparities; eliminating these disparities will require culturally appropriate public health initiatives, community support, and equitable access to quality health care.
Correction: The allergy business
Journal: BMJ (1990)

Each year I have 850 new inpatients and 600 new outpatients under my own personal care, a not dissimilar figure to most district general hospital physicians I guess.Even a genius or a saint could not hope to sort out all ofthese perfectly, and ifonly 1% ofcustomers went through the whole complaints pro- cedure then the effect would be startlingly disruptive.The curious paradox is that most patients and their relatives tend to be forgiving of mishaps and grateful for con- scientious medical attention.Unsatisfactory outcomes are generally viewed as bad luck despite best efforts.The virulence of the complaint often seems inversely proportional to any justification.There is scope for damag-
Étude SUR le TRAITEMENT de LA Tuberculose Pulmonaire.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply:
Authors: Yaakov Nahmias, Martin L. Yarmush, Raymond T. Chung
Journal: Hepatology (2008)

We are pleased that Dr. Morcos and colleagues have raised the issue of potential drug-drug interactions due to grapefruit consumption. Our work, using the JFH1/Huh7.5.1 full life-cycle model of hepatitis C virus (HCV) demonstrated that the virus is actively secreted by the cells while bound to very low density lipoprotein. This viral dependence on the cholesterol pathway suggests a new therapeutic target and an arsenal of compounds previously developed against arteriosclerosis. One of these compounds is the grapefruit flavonoid naringenin, a nontoxic antioxidant with demonstrated anticarcinogenic properties.1 Although our work demonstrated that naringenin effectively inhibits HCV secretion in vitro, these results have not been clinically validated. It is for this reason that we felt that a full discussion of the potential drug-drug interactions was beyond the scope of our original submission. However, the widespread interest in our results suggests that this discussion is warranted. As noted by Dr. Morcos and colleagues, several furanocoumarin and flavonoids in grapefruit are known to have significant interactions with drugs including: calcium channel blockers prescribed for high blood pressure, cholesterol lowering drugs, anti-anxiety drugs such as Buspar (buspirone), birth control pills, as well as the epilepsy drug Tegretol (carbamazepine). In addition, patients on immunosuppressive medication such as Neoral (ciclosporin) or those taking protease inhibitors used to treat human immunodeficiency virus such as Norvir (ritonavir) may be in particular risk. An effect of naringenin on amphibian embryonic development has also been reported.2 A partial list of affected drugs is presented in Table 1. In spite of this danger, we feel that the wide reach and rapid uptake of our work among the general public is inspiring because it demonstrates that the average patient in today's information-rich environment is actively searching for the latest research findings. In many cases, this new-found information can rapidly improve the life of patients, but in some cases overinterpretation or misunderstanding of research results could lead to undesirable effects. This potential for good or ill requires a new degree of openness from the research and medical community and a willingness to provide critical information to help patients make educated choices. In the meantime, we note that lowering cholesterol and improving your diet to include antioxidants from many fruits and vegetables has always been sound advice. It is even more important now that this link between HCV and cholesterol has been established. Yaakov Nahmias Ph.D.* , Martin L. Yarmush M.D., Ph.D.* , Raymond T. Chung M.D. , * Center for Engineering in Medicine, Shriners Burn Hospital, Boston, MA, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract 12849: Changes in N-terminal Pro Brain Natriuretic Peptide Levels Predicts Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction
Authors: Gianluigi Savarese, Camilla Hage, Ulf Dahlström, Pasquale Perrone-Filardi, Lars H Lund
Journal: Circulation (2015)

Introduction: Changes in N-terminal pro brain natriuretic peptide (NT-proBNP) have been demonstrated to correlate with outcomes in patients with heart failure (HF) and reduced ejection fraction (EF). However the prognostic value of a change in NT-proBNP in patients with heart failure and preserved ejection fraction (HFPEF) is unknown. Hypothesis: To assess the impact of changes in NT-proBNP on all-cause mortality, HF hospitalization and their composite in an unselected population of patients with HFPEF. Methods: 643 outpatients (age 72+12 years; 41% females) with HFPEF (ejection fraction ≥40%) enrolled in the Swedish Heart Failure Registry between 2005 and 2012 and reporting NT-proBNP levels assessment at initial registration and at follow-up were prospectively studied. Patients were divided into 2 groups according the median value of NT-proBNP absolute change that was 0 pg/ml. Median follow-up from first measurement was 2.25 years (IQR: 1.43 to 3.81). Adjusted Cox’s regression models were performed using total mortality, HF hospitalization (with censoring at death) and their composite as outcomes. Results: After adjustments for 19 baseline variables including baseline NT-proBNP, as compared with an increase in NT-proBNP levels at 6 months (NT-proBNP change&gt;0 pg/ml), a reduction in NT-proBNP levels (NT-proBNP change&lt;0 pg/ml) was associated with a 45.2% reduction in risk of all-cause death (HR: 0.548; 95% CI: 0.378 to 0.796; p:0.002), a 50.1% reduction in risk of HF hospitalization (HR: 0.49; 95% CI: 0.362 to 0.689; p&lt;0.001) and a 42.6% reduction in risk of the composite outcome (HR: 0.574; 95% CI: 0.435 to 0.758; p&lt;0.001)(Figure). Conclusions: Reductions in NT-proBNP levels over time are independently associated with an improved prognosis in HFPEF patients. Changes in NT-proBNP could represent a surrogate outcome in phase 2 HFPEF trials.
The Medical Department of the United States Army in the World War.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification of a polyI:C-inducible membrane protein that participates in dendritic cell–mediated natural killer cell activation
Authors: Takashi Ebihara, Masahiro Azuma, Hiroyuki Oshiumi, Jun Kasamatsu, Kazuya Iwabuchi, Kenji Matsumoto, Hirohisa Saito, Tadatsugu Taniguchi, Misako Matsumoto, Tsukasa Seya
Journal: The Journal of Experimental Medicine (2015)
Purple Urine
Authors: Eli Ben-Chetrit, Gabriel Munter
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Computers, Amplifiers Study Brain's Electronic Impulses
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lung Dysfunction and Chronic Liver Disease
Authors: Paul A. Lange
Journal: Annals of Internal Medicine (1996)

Letters1 February 1996Lung Dysfunction and Chronic Liver DiseasePaul A. Lange, MD and James K. Stoller, MDPaul A. Lange, MDCleveland Clinic Foundation; Cleveland, OH 44106Search for more papers by this author and James K. Stoller, MDCleveland Clinic Foundation; Cleveland, OH 44106Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-3-199602010-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail response: Dr. Brodkin points out the symptomatic and functional improvement that accompanied coil-spring embolization in the patient described by Felt and colleagues [1]. Although the published study did not describe the patient's improvement in dyspnea and exercise capacity, we agree that these unstated benefits shed a more optimistic light on the effect of the embolization. However, the modest improvement in oxygenation (an increase in room air Pao2 from 38 mm Hg to 53 mm Hg) and the persistence of orthodeoxia (despite the deployment of 22 coils in three separate procedures) does justify some reservations. Furthermore, as with liver transplantation for ...References1. Felt RW, Kozak BE, Rosch J, Duell BP, Barker AF. Hepatogenic pulmonary angiodysplasia treated with coil-spring embolization. Chest. 1987; 91:920-2. Google Scholar2. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med. 1995; 122:521-9. Google Scholar3. Hamdani R, Chelluri L, Selby R, Kramer D, Kang Y, Wood S, Van Thiel D. Sudden death in patients with pulmonary hypertension undergoing orthotopic liver transplantation. AASLD Abstracts. Hepatology. 1991; 14:282A. Google Scholar4. Koneru B, Ahmed S, Weisse AB, Grant GP, McKim KA. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation. 1994; 58:1133-5. Google Scholar5. Bero LA, Glantz SA, Romnie D. Publication bias and public health policy on environmental tobacco smoke. JAMA. 1994; 272:133-6. Google Scholar Author, Article, and Disclosure InformationAffiliations: Cleveland Clinic Foundation; Cleveland, OH 44106 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1996Volume 124, Issue 3Page: 369-370KeywordsChronic liver diseaseDyspneaExerciseHypertensionInformation technologyLiver diseasesLiver transplantationLungsPulmonary hypertension ePublished: 15 August 2000 Issue Published: 1 February 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control
Authors: Eugene T Richardson, Robin Wood
Journal: New England Journal of Medicine (2014)

Third, socioeconomic status is a stronger predictor of obesity among normal-weight children than among overweight children.The relative risk of becoming obese among children with lower socioeconomic status compared with children with higher socioeconomic status was greater for normal-weight kindergartners than for overweight kindergartners.The patterns of the incidence of obesity during childhood indicate the complexities of the socioeconomic context of this health problem and the reach of the risk of obesity across the socioeconomic spectrum in the United States.
Medizinische Toxikologie: Lehrbuch für Ärzte, Apotheker und Chemiker
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Vitro and in Vivo Estrogenicity of UV Screens
Authors: Margret Schlumpf, Beata Cotton, Marianne Conscience, Vreni Haller, Beate Steinmann, Walter Lichtensteiger
Journal: Environmental Health Perspectives (2001)

Ultraviolet (UV) screens are increasingly used as a result of growing concern about UV radiation and skin cancer; they are also added to cosmetics and other products for light stability. Recent data on bioaccumulation in wildlife and humans point to a need for in-depth analyses of systemic toxicology, in particular with respect to reproduction and ontogeny. We examined six frequently used UVA and UVB screens for estrogenicity in vitro and in vivo. In MCF-7 breast cancer cells, five out of six chemicals, that is, benzophenone-3 (Bp-3), homosalate (HMS), 4-methyl-benzylidene camphor (4-MBC), octyl-methoxycinnamate (OMC), and octyl-dimethyl-PABA (OD-PABA), increased cell proliferation with median effective concentrations (EC(50)) values between 1.56 and 3.73 microM, whereas butyl-methoxydibenzoylmethane (B-MDM) was inactive. Further evidence for estrogenic activity was the induction of pS2 protein in MCF-7 cells and the blockade of the proliferative effect of 4-MBC by the estrogen antagonist ICI 182,780. In the uterotrophic assay using immature Long-Evans rats that received the chemicals for 4 days in powdered feed, uterine weight was dose-dependently increased by 4-MBC (ED(50 )309mg/kg/day), OMC (ED(50) 935 mg/kg/day), and weakly by Bp-3 (active at 1,525 mg/kg/day). Three compounds were inactive by the oral route in the doses tested. Dermal application of 4-MBC to immature hairless (hr/hr) rats also increased uterine weight at concentrations of 5 and 7.5% in olive oil. Our findings indicate that UV screens should be tested for endocrine activity, in view of possible long-term effects in humans and wildlife.
Cowden's Disease: A Possible New Symptom Complex with Multiple System Involvement
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal